Pulmatrix (NASDAQ:PULM) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Pulmatrix (NASDAQ:PULM) from a hold rating to a buy rating in a research report released on Thursday morning, Zacks.com reports. The firm currently has $1.00 price objective on the biotechnology company’s stock.

According to Zacks, “Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company’s proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA. “

Separately, ValuEngine upgraded Pulmatrix from a hold rating to a buy rating in a report on Tuesday, August 6th.

Shares of Pulmatrix stock opened at $0.81 on Thursday. The firm has a market cap of $15.89 million, a price-to-earnings ratio of -0.16 and a beta of 1.31. The business has a fifty day simple moving average of $0.89 and a 200-day simple moving average of $1.04. Pulmatrix has a fifty-two week low of $0.72 and a fifty-two week high of $4.70.

A hedge fund recently raised its stake in Pulmatrix stock. Vanguard Group Inc. raised its holdings in Pulmatrix Inc (NASDAQ:PULM) by 26.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 87,634 shares of the biotechnology company’s stock after buying an additional 18,250 shares during the quarter. Vanguard Group Inc. owned approximately 0.45% of Pulmatrix worth $81,000 at the end of the most recent quarter. Institutional investors own 3.52% of the company’s stock.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD).

See Also: Exchange-Traded Funds (ETFs)

Get a free copy of the Zacks research report on Pulmatrix (PULM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.